Related Experiment Video
Updated: Sep 27, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
[Porphyria cutanea tarda, hemodialysis and HCV hepatopathy]
S Muray1, J M Casanova, M P Marco
1Servicio de Nefrología, Hospital Universitari Arnau de Vilanova de Lleida, Rovira Roure, 80 25198 Lleida.
Porphyria cutanea tarda is treated with phlebotomies in the absence of renal failure. However, in patients on maintenance hemodialysis, this will lead to the need for high doses of erythropoietin. We describe the case of a 63-year-old hemodialysis patient who had chronic hepatitis C virus and developed porphyria cutanea tarda after iron overload due to repeated transfusions. She was treated with erythropoietin and phlebotomies reaching clinical remission 4 months after beginning treatment.
Porphyria cutanea tarda is treated with phlebotomies in the absence of renal failure. However, in patients on maintenance hemodialysis, this will lead to the need for high doses of erythropoietin. We describe the case of a 63-year-old hemodialysis patient who had chronic hepatitis C virus and developed porphyria cutanea tarda after iron overload due to repeated transfusions. She was treated with erythropoietin and phlebotomies reaching clinical remission 4 months after beginning treatment.
Related Concept Videos
Hemodialysis II: Procedure and Complications
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Hemodialysis I: Introduction
Hemodialysis III: Nursing Management
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration